• Home
  • Latest
  • Coins2Day 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
FeaturesHealth

‘Open Humans’ platform wants to democratize your DNA for better medical research

By
Laura Lorenzetti
Laura Lorenzetti
Down Arrow Button Icon
By
Laura Lorenzetti
Laura Lorenzetti
Down Arrow Button Icon
March 24, 2015, 11:06 AM ET
<h1>DNA Rx</h1>


In 2003, a team of researchers working for the Department of Energy and the National Institutes of Health completed a 13-year long effort called the Human Genome Project. The goal of the project was, among other things, to identify and map every gene in human DNA. For a while, the scientific community has been looking at the data and wondering, "So, what's next?" 


One answer is targeted therapy, medical treatments that do not only address symptoms, but also respond to a patient's genetic makeup. 


The past couple of years have yielded breakthroughs in this field. In 2011, a team of scientists at the University of Pennsylvania effectively treated leukemia patients by engineering their own white blood cells to fight the disease. Also in 2011, researchers in Britain achieved promising results in treating the genetic disease hemophilia B by injecting patients with a re-engineered version of the gene. 2012 brought even more advancements, using targeted therapy to treat inherited blindness.


"Talk about transforming an industry," says George Day, co-director of the Mack Center at Wharton. "Big Pharma has always been pill-based," he says, meaning patients need daily dosage, whereas "gene therapy is one and done.


"I think finally after 20 years, the promise of gene therapy is starting to be realized."
<h1>DNA Rx</h1> In 2003, a team of researchers working for the Department of Energy and the National Institutes of Health completed a 13-year long effort called the Human Genome Project. The goal of the project was, among other things, to identify and map every gene in human DNA. For a while, the scientific community has been looking at the data and wondering, "So, what's next?" One answer is targeted therapy, medical treatments that do not only address symptoms, but also respond to a patient's genetic makeup. The past couple of years have yielded breakthroughs in this field. In 2011, a team of scientists at the University of Pennsylvania effectively treated leukemia patients by engineering their own white blood cells to fight the disease. Also in 2011, researchers in Britain achieved promising results in treating the genetic disease hemophilia B by injecting patients with a re-engineered version of the gene. 2012 brought even more advancements, using targeted therapy to treat inherited blindness. "Talk about transforming an industry," says George Day, co-director of the Mack Center at Wharton. "Big Pharma has always been pill-based," he says, meaning patients need daily dosage, whereas "gene therapy is one and done. "I think finally after 20 years, the promise of gene therapy is starting to be realized." Illustration: Alfred Pasieka/Getty Images

Get ready to share more than photos of your latest vacation.

A new online platform launched Tuesday allows users to share data about their genomes, gut bacteria and other biological data with scientists and researchers.

The “Open Humans Network,” backed by the Knight Foundation and Robert Wood Johnson Foundation, aims to make more data available for researchers across studies. Its goal is to democratize valuable information that study leaders have typically held secret in order to prevent access by others. The fear is that a competitor could beat them to an important discovery.

Geneticist George Church of Harvard University said that such DNA data are also valuable to gene-testing companies — those companies can profit from the data too, he said.

But the mindset of secrecy slows down important medical research that could lead to breakthroughs on anything from cancer treatments to better flu vaccines.

Open Humans hopes to break that pattern by allowing universal access to the data stored on the site by researchers on other projects. Unlike other “de-identified” data, it will come with names and contact information attached so scientists can follow up with users.

Project director Jason Bobe compares it to other tech platforms: “It’s like open-sourcing your body,” he said.

The site currently hosts three studies that users can sign up for: American Gut looks at the relationship between gut bacteria and disease; GoViral identifies what viruses are circulating during flu season in the U.S.; and the Personal Genome Project, led by Church, gathers DNA data to make connections between genomic patterns and health.

Users allow any legitimate user to access their information when they sign up, which raises potential privacy concerns. In order to sign up, participants must pass a test showing they understand the risks of sharing private health information. If hacked, the leaked information could affect a person’s access to life insurance, or long-term care coverage.

—Reuters contributed to this report.
[Coins2Day-brightcove videoid=4109993040001]

About the Author
By Laura Lorenzetti
See full bioRight Arrow Button Icon

Latest in Features

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Features

Bill Gates and Warren Buffett.
InvestingWarren Buffett
Warren Buffett’s blind spot: Did the digital economy leave him behind?
By Adam SeesselDecember 30, 2025
16 days ago
Photo of Sam Altman
AIOpenAI
Inside OpenAI’s fragile lead in the AI race, and the 8-week ‘code red’ to fend off a resurgent Google
By Jeremy Kahn, Alexei Oreskovic and Lee CliffordDecember 17, 2025
29 days ago
FeaturesThe Boring Company
Two firefighters suffered chemical burns in a Boring Co. tunnel. Then the Nevada Governor’s office got involved, and the penalties disappeared
By Jessica Mathews and Leo SchwartzNovember 12, 2025
2 months ago
CoreWeave executives pose in front of the Nasdaq building on the day of the company's IPO.
AIData centers
Data-center operator CoreWeave is a stock-market darling. Bears see its finances as emblematic of an AI infrastructure bubble
By Jeremy Kahn and Leo SchwartzNovember 8, 2025
2 months ago
Libery Energy's hydraulic fracturing, or frac, spreads are increasingly electrified with natural gas power, a technology now translating to powering data centers.
Energy
AI’s insatiable need for power is driving an unexpected boom in oil-fracking company stocks 
By Jordan BlumOctober 23, 2025
3 months ago
Politics
Huge AI data centers are turning local elections into fights over the future of energy
By Sharon GoldmanOctober 22, 2025
3 months ago

Most Popular

placeholder alt text
Personal Finance
Peter Thiel makes his biggest donation in years to help defeat California’s billionaire wealth tax
By Nick LichtenbergJanuary 14, 2026
18 hours ago
placeholder alt text
AI
'Godfather of AI' says the technology will create massive unemployment and send profits soaring — 'that is the capitalist system'
By Jason MaJanuary 12, 2026
3 days ago
placeholder alt text
Success
Despite his $2.6 billion net worth, MrBeast says he’s having to borrow cash and doesn’t even have enough money in his bank account to buy McDonald’s
By Emma BurleighJanuary 13, 2026
2 days ago
placeholder alt text
AI
Being mean to ChatGPT can boost its accuracy, but scientists warn you may regret it
By Marco Quiroz-GutierrezJanuary 13, 2026
2 days ago
placeholder alt text
Future of Work
'Microshifting,' an extreme form of hybrid working that breaks work into short, non-continuous blocks, is on the rise
By Nick LichtenbergJanuary 13, 2026
2 days ago
placeholder alt text
Economy
Goldman Sachs top economist says Powell probe won’t change the Fed: 'Decisions are going to be made based on employment and inflation'
By Sasha RogelbergJanuary 12, 2026
3 days ago

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.